We have examined the in¯uence of insulin-like growth factor I (IGF-1) on prolactin gene expression in rat pituitary GH4C1 cells. Incubation with IGF-1 increases prolactin mRNA levels and activates the prolactin promoter in transient transfection assays. A similar degree of activation is observed with constructs extending to 73000 and 7176 base pairs of the prolactin 5' anking region, indicating that the IGF-1 response element is located in the proximal promoter sequences. A plasmid containing 101 base pairs shows a partial stimulation by IGF-1, and the response is lost in a deletion to 776 base pairs. The Ras oncoproteins have been implicated as a critical signaling component in mediating the eect of growth factor receptor tyrosine kinases. Expression of oncogenic Ras
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Val12 mimics the eect of IGF-1 on the prolactin promoter, and a dominant negative Ras, Ras Asn17 , blocks IGF-1-mediated stimulation. Dominant negative mitogen-activated protein kinase (MAPK) also reduces the activation of the prolactin promoter by IGF-1. Ets transcription factors have been described to lie downstream of Ras and MAPK in the signaling pathway leading to prolactin gene activation. Mutation of two Ets binding sites in the promoter region between 7101 and 776 abolishes the response to IGF-1. Furthermore, a dominant negative Ets vector strongly reduces the response of the prolactin promoter to IGF-1 and Ras. The endogenous concentration of Ets-related proteins is not limiting in GH4C1 cells for the IGF-1 eect. However, c-Ets-1 and GHF-1 act synergistically in HeLa cells with the IGF-1 receptor, reconstituting pituitary IGF-1 responsiveness. The response to IGF-1 in GH4C1 cells is still observed after transfection with Ras Val12 suggesting that, although Ras is required, IGF-1 could stimulate other pathway/s in addition to Ras. Wortmanin, an inhibitor of phosphatidylinositol-3 kinase (Pl-3 kinase), also prevents the response of the prolactin promoter to IGF-1. These results show that both the Ras/MAPK/Ets pathway, as well as the activation of Pl-3 kinase are involved in the signaling mechanism leading to prolactin expression by IGF-1 in GH4C1 cells.
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Introduction
Multiple hormones, growth factors and oncogenes act in conjunction with the pituitary-speci®c transcription factor GHF-1 (also called Pit-1) to regulate pituitaryspeci®c expression of the prolactin gene. Ligands of several members of the superfamily of nuclear receptors, including estrogens, glucocorticoids, or thyroid hormones regulate positive or negatively prolactin gene expression (Camper et al., 1985; Day and Maurer, 1989; Day et al., 1990; Stanley, 1989) . Transcription of the prolactin gene is also modulated by a number of ligands which bind to plasma membrane receptors such as dopamine, thyrotropin releasing hormone (TRH), epidermal growth factor (EGF) and insulin (Berwaer et al., 1993; Camper et al., 1985; Elsholtz et al., 1986 Elsholtz et al., , 1991 Iverson et al., 1990; Murdoch et al., 1985; Supowitz, 1984; Stanley, 1988 Stanley, , 1992 . Furthermore, prolactin gene expression is stimulated by activation of the protein kinase A (PKA) and the protein kinase C (PKC) pathways (Conrad and Gutierrez-Hartmann, 1992; Jacob and Stanley, 1994; Maurer, 1981; Oberwetter et al., 1993) .
Expression of a constitutively active ras oncogene in GH4 pituitary cells also produces a strong activation of the prolactin promoter, and Src expression in these cells activates this promoter via a Ras-dependent mechanism (Conrad and Gutierrez-Hartmann, 1992; Conrad et al., 1994; Pickett and Gutierrez-Hartmann, 1994) . In contrast, PKA and PKC produce enhancement of the activity of the prolactin promoter by mechanisms that are antagonistic to the Ras pathway (Conrad and Gutierrez-Hartmann, 1992; Oberwetter et al., 1993) . Although the ras oncogenes play an important role in the signal transduction pathways used by dierent tyrosine kinase growth factor receptors, EGF produces signi®cant stimulation of prolactin promoter activity via a Ras-independent mechanism Gutierrez-Hartmann, 1994, 1995) . Taken together these observations suggest the existence of a cross-talk between dierent signaling pathways to determine the degree of expression of the prolactin gene in pituitary cells.
It has been shown that Raf, MAPK and Ets are crucial components of the downstream transmission of the Ras signal in the regulation of prolactin promoter activity (Bradford et al., 1995 (Bradford et al., , 1996 . The Ets family of transcription factors comprises a number of phosphoproteins with a conserved DNA-binding motif named the Ets domain (Macleod et al., 1992; Wasylyk et al., 1993) . Several Ets-binding sites have been identi®ed in the proximal prolactin promoter. Ets-1 and GHF-1 act synergistically with oncogenic Ras and Raf to stimulate prolactin promoter activity, and a functional interaction between Ets and GHF-1 is required for an optimal Ras response (Bradford et al., 1995) . The Ras-Ets cooperative activation of prolactin transcription has been described to colocalize with the Ets-binding site located at 7217 to 7209 (Bradford et al., 1996) . The GHF-1 binding site at 7150/7165 also contains an overlapping Etsbinding site. A speci®c mutation of this Ets motif, which does not aect GHF-1 binding, greatly decreases the ability of EGF, phorbol esters, Ras and Raf to induce reporter gene activity, suggesting that this sequence is important to permit transcriptional regulation of the prolactin gene by dierent signaling pathways (Howard and Maurer, 1995) . In addition, the insulin response element, that overlaps the cAMP response element, is located in region 767/ 97 and contains a direct repeat of the Ets-binding sequence CGGAAA (Jacob and Stanley, 1994) . A dominant-negative Ets protein inhibits insulin-increased prolactin gene expression (Jacob et al., 1995) . MAPK activity is increased in insulin-treated cells and phosphorylates GABPa, a member of the Ets family. Therefore, it has been suggested that GABP mediates insulin-increased transcription of the prolactin gene (Ouyang et al., 1996) .
Insulin-like growth factor 1 (IGF-1) elicits a number of biological responses, including changes in cell proliferation, dierentiation and gene expression in a variety of cell types. IGF-1 has been described to inhibit growth hormone (GH) transcription in primary rat pituitary cells and in pituitary cell lines Melmed, 1986, 1987; Prager and Melmed, 1988) , although stimulation of GH gene expression by insulin in GH3 cells has also been described (Stanley, 1988) . These responses are mediated by ligand activation of a tyrosine kinase receptor. Previous studies have shown that signi®cant numbers of IGF-1 receptors are expressed in rat pituitary cell lines . Binding of IGF-1 is followed by a rapid activation of the intrinsic tyrosine activity of the receptor, resulting in activation of Ras and consequently the intracellular kinase cascades. Raf, MEK and MAP kinases are downstream components of this pathway, which has been shown to result in phsophorylation of numerous substrates including nuclear transcription factors. A rapid and strong activation of MAPK activity by IGF-1 has been recently described in the rat pituitary cell lines (Castillo and Aranda, 1997; Webster et al., 1994) . It has been also shown that ligand-activation of the IGF-1 receptors results in the initiation of other signaling pathway that involves activation of phosphatidylinositol-3 kinase (Pl-3 kinase) and subsequent formation of the putative second messenger phosphatidylinositol-3 phosphate (PIP 3 ) (Myers et al., 1992) . A role of this pathway in pituitary gene expression has not yet been reported.
In this study we have compared the regulation of prolactin, growth hormone and GHF-1 gene expression in pituitary GH4C1 cells. Our results show that IGF-1 induces prolactin gene expression, without aecting GH or GHF-1. The induction of the prolactin gene is mediated by sequences located in the proximal promoter and requires both Pl-3 kinase activity and functional Ras, MAPK and Ets. Figure 1 compares the eect of a 48 h incubation with 13 nM IGF-1 on prolactin, GH and GHF-1 mRNA. IGF-1 increased by more than fourfold prolactin transcripts without signi®cantly altering GH or GHF-1 mRNA levels. The eect of IGF-1 was compared with that induced by other known regulators of prolactin gene expression. The thyroid hormone T3 has been described to inhibit prolactin gene expression in GH1 cells (Stanley, 1989) . Alternatively, T3 stimulates prolactin mRNA in GH3 cells (Day and Maurer, 1989) . Figure 1 shows that treatment with 5 nM T3 for 48 h induces prolactin mRNA levels in GH4C1 cells. Prolactin transcripts also increased in cells incubated in the presence of 10 mM forskolin that induces cAMP. The induction caused by IGF-1 was stronger than that produced by T3 or forskolin. In contrast, IGF-1 did not increase GH transcripts which were signi®cantly stimulated by T3 and to a lesser extent by forskolin. In accordance with our previous observations T3 signi®cantly reduced GHF-1 mRNA levels (Sanchez-Pacheco et al., 1995) , and these levels were not aected by IGF-1. Since the eect of cAMP on the GHF-1 gene is very transient, GHF-1 transcripts were not elevated after 48 h of incubation with forskolin.
Results

IGF-1 selectively increases Prl-mRNA levels in GH4C1 cells
In¯uence of IGF-1 on prolactin promoter activity in GH4C1 cells
The expression of the prolactin gene is regulated through protein interactions with its 5'-¯anking region. A distal enhancer region about 1.5 kilobases upstream from the transcription initiation site, as well as a proximal promoter region contain sequences contributing to cell-speci®c expression and hormonal regulation (Nelson et al., 1988) . Experiments in which GH4C1 cells were transfected with Prl-CAT constructs containing 3000 basepairs of the rat prolactin promoter are shown in Figure 2 . Incubation with IGF-1 produced a signi®cant increase of CAT activity (3.2+0.2-fold in three dierent experiments) in cells transfected with the 73000Prl-CAT construct. IGF-1 has a signi®cant eect on GH4C1 cell protein levels, increasing total protein content of the cultures by approximately 1.5 ± 2-fold. Since CAT activity is determined using the same amount of protein in control and IGF-1 treated cells, and plasmids do not replicate, the stimulation of promoter activity by IGF-1 is likely to be underestimated. If corrected by this factor, IGF-1 increases prolactin promoter activity by approximately ®vefold. The amount of IGF-1 receptors are limiting in GH4C1 cells for the stimulation of the prolactin promoter, since the response to IGF-1 increased to more than 15-fold in cells transfected with an expression vector for the IGF-1 receptor (not illustrated). T3 and forskolin also increased the activity of the 73000Prl-CAT constuct, and the eect of IGF-1 and these compounds was additive. Since the 73000Prl-CAT construct contains an AP-1 binding site in the plasmid backbone which could be activated by PKA and PKC and interfere the eect of the T3 receptor (Kushner et al., 1994) , this site was deleted in the 7D3000Prl-CAT construct. As shown in the ®gure, regulation of this plasmid by the dierent factors was identical to that found in the parental construct, thus showing that this element is not involved in the regulation of the prolactin promoter by these compounds in GH4C1 cells. The proximal region of the prolactin gene is sucient to mediate transcriptional responses to several hormones. Since insulin and IGF-1 have a similar mechanism of action and sequences that confer responsiveness to insulin are located between 767 and 797, we also tested the eect of IGF-1 in the shorter CAT constructs 7176Prl-CAT and 7176DPrl-CAT. Figure 2 illustrates the results obtained with the AP-1-deleted construct, which were the same as those obtained with 7176Prl-CAT. IGF-1 increased the activity of the proximal prolactin promoter to an extent similar to that found with 73000Prl-CAT (approximately threefold). Similar results were obtained with the 7423Prl-CAT constructs (not shown). The possibility that the stimulation of the prolatin promoter may re¯ect binding of IGF-1 to the insulin receptor rather than a bona ®de IGF-1 receptor mediated eect can be dismissed, since incubation with insulin at concentrations similar to those of IGF-1 used here were unable to aect the prolactin promoter in GH4C1 cells (Castillo and Aranda, 1997) . As expected, forskolin also had an stimulatory eect on the 7176DPrl-CAT construct, and again CAT activity was maximal in the presence of IGF-1 and forskolin together. In contrast, T3 did not have an stimulatory eect on this promoter fragment, and partially blocked the induction of IGF-1.
To further map the promoter sequences responsible for IGF-1 regulation, the eect of the growth factor on the activity of shorter CAT promoter constructs (7D101Prl-CAT and 7D76Prl-CAT) was compared with that observed with the plasmid extending to 7176 basepairs. To better resolve the eect of IGF-1, this mapping was performed in cells transfected with an expression vector for the IGF-1 receptor. As shown in Figure 3 , under these conditions IGF-1 exposure produced a very strong activation (18-fold) of the 7D176Prl-CAT promoter construct. Deletion to 7101 decreased IGF-1 dependent activation, but a signi®cant sixfold response was still found. However, the promoter plasmid extending to 776 bp had a very low basal activity and was not stimulated by IGF-1, suggesting that the 7101 to 776 region is necessary for IGF-1 activation. Con®rming previous observations, the cAMP response also mapped to this region that contains a cAMP response element (CRE) (Jacob and Stanley, 1994 ). An Ets binding site that is required for insulin regulation is deleted in the construct 7D76 Prl-CAT that does not respond to IGF-1. It has been described that insulin responsiveness of the prolactin gene can be eliminated by mutation of the sequences at 796/787 and 776/767 of the prolactin promoter which contain the Ets motifs (Jacob et al., 1995) . To analyse whether these sequences are also involved in IGF-1 responsiveness, they were mutated in the 7D101Prl-CAT to give the 7Dmut101Prl-CAT construct. These mutations signi®cantly decreased basal promoter activity and totally abolished the response to IGF-1, showing that these sequences are involved in the eect of IGF-1 on the prolactin promoter. The response to forskolin of this plasmid, in which the overlapping CRE has been altered, was also abolished.
The eect of IGF-1 was speci®c for the prolactin promoter. The growth factor does not signi®cantly induce GH promoter activity in GH4C1 cells. This promoter was strongly activated by T3, and to a lesser extent by forskolin, and IGF-1 did not alter these Figure 2 Stimulation of prolactin promoter activity by IGF-1, triiodothyronine and forskolin. GH4C1 cells were transfected with 10 mg of the following prolactin-CAT constructs: 73000Prl-CAT (containing the fragment 73000/+75 of the rat prolactin gene), 7D3000Prl-CAT (in which sequences of the plasmid backbone containing an AP-1 site have been deleted), and 7D176Prl-CAT (containing the fragment 7176/+75 of the rat prolactin gene). After transfection, control cells (7) and cells treated with 5 nM T3 or 10 mM forskolin (Fk), were incubated for 48 h in the presence (black bars) or absence (light bars) of 13 nM IGF-1. Cells were then harvested and CAT activity determined. A representative experiment is shown; the data represent the mean+standard deviation of three independent transfections responses. IGF-1 was also ineective in regulating basal GHF-1 promoter activity or in modulating the response of this gene to forskolin or the phorbol ester TPA (data not shown).
Eect of oncogenic-and dominant-negative Ras mutants on IGF-1 activation of the prolactin promoter
It has been previously demonstrated that oncogenic Ras signi®cantly increases prolactin promoter activity in pituitary cells (Conrad and Gutierrez-Hartmann, 1992; Conrad et al., 1994; Howard and Maurer, 1995) . Since binding of IGF-1 to its cell surface receptors is followed by rapid activation of the intrinsic tyrosine kinase activity of the receptors and a subsequent phosphorylation cascade in which activation of Ras plays an important role, it was of interest to analyse the in¯uence of this oncogene on the regulation of the prolactin promoter by IGF-1. Figure 4 compares the eect of oncogenic Ras
Val12 on prolactin promoter activity in GH4C1 cells treated with IGF-1 alone or in combination with T3 or forskolin. In agreement with previous observations in pituitary cells, expression of oncogenic Ras strongly activated the 7D3000Prl-CAT construct in GH4C1 cells (Figure 4a ). Forskolin did not stimulate but rather decreased promoter activity in cells expressing Ras, in agreement with the ®nding that the Ras and protein kinase A pathways are mutually antagonistic in regulating rat prolactin promoter activity (Conrad and Gutierrez-Hartmann, 1992) . Surprisingly, T3 also antagonized the induction of Ras, and in the presence of this hormone the promoter showed a reduced response to activated Ras. In contrast, IGF-1 was able to potentiate the eect of Ras Val12 on this promoter, and to increase CAT activity above the levels found in cells treated with forskolin, antagonizing the inhibitory eect of the protein kinase A activator. This eect appears to be speci®c because IGF-1 did not block the antagonism caused by T3.
It has been previously reported that a composite Ets-GHF-1 binding site located at 7217 to 7209 is required to mediate activation of the prolactin promoter by oncogenic Ras (Bradford et al., 1995 (Bradford et al., , 1996 . However, as shown in panel B, expression of Ras Val12 also strongly induced the activity of the 7D176Prl-CAT plasmid. This response was lost when the promoter was deleted to 770 basepairs (data not shown). T3, that had a slight inhibitory eect on the 7D176Prl-CAT plasmid in the absence of Ras, had a . CAT activity was determined 48 h after transfection in control cells (C) and in cells treated with 5 nM T3 or 10 mM forskolin (Fk) in the presence or absence of 13 nM IGF-1. The data are mean+standard deviation of the values obtained from 2 ± 3 dierent experiments performed in duplicate potent inhibitory eect in the presence of the oncogene. Again IGF-1 was able to activate the promoter in control and forskolin-treated cells expressing Ras, but could not antagonize the repressive eect of T3.
To unequivocally demonstrate that the endogenous Ras signaling pathway is involved in the regulation of the prolactin gene by IGF-1, co-transfection studies with a vector encoding the dominant negative Ras Asn17 mutant were also performed ( Figure 5 ). This mutant reduced the extent of the induction of the 7D3000Prl-CAT caused by IGF-1 (left panel). This suppression was speci®c for the IGF-1 action, since the stimulatory eect of T3 and forskolin was not signi®cantly altered by the dominant inhibitory Ras. The mutant Ras also suppressed the additive eect of T3 + IGF-1 or forskolin + IGF-1 on CAT levels. Similar results were obtained when the proximal prolactin promoter was cotransfected with Ras Asn17 (right panel): the mutant totally repressed the eect of IGF-1, but did not signi®cantly aect forskolin-mediated induction or the inhibitory eect of T3.
Since MAPK acts downstream of Ras in the signaling pathway of tyrosine kinase receptors, we also examined the in¯uence of a dominant-negative MAPK on the stimulation of the prolactin promoter by IGF-1. Figure 6 shows that expression of a kinasede®cient MAPK speci®cally reduced IGF-1-induced stimulation without altering the increase due to either T3 or forskolin. This con®rms that IGF-1 uses the Ras/MAPK pathway to elicit prolactin gene expression in GH4C1 cells, whereas this pathway is not involved in regulation by T3 or cAMP.
Role of Ets on the response of the prolactin promoter to IGF-1
Previous studies from other laboratories have suggested that Ets transcription factors mediate the response of the prolactin gene to Ras (Bradford et al., 1995 (Bradford et al., , 1996 and insulin (Jacob et al., 1995) , and the results illustrated in Figure 3 showed the requirement of the Ets binding sites in the promoter for IGF-1 induction. To functionally determine if Ets transcription factors are the nuclear acceptors for the IGF-1 response, we examined the in¯uence of over-expression of c-Ets-1 alone or in combination with GHF-1, GHF-2 and Ras on IGF-1-mediated activation of the prolactin promoter. Transfection with an expression vector encoding c-Ets-1 did not increase basal promoter activity in GH4C1 cells. In addition, the response to IGF-1 was not modi®ed in the presence of excess amounts of the transcription factor. The stimulatory eect of T3 and forskolin was also identical. Similar results were obtained when GH4C1 cells were transfected with an expression vector encoding ERM, other member of the Ets family of transcription factors (data not shown). These results suggest that, if Ets factors are required for the eect of IGF-1, their endogenous levels are not limiting in GH4C1 cells for this eect. However, the c-Ets-1 vector greatly increased the activity of the prolactin promoter construct in HeLa cells (Figure 7a) . Transfection with c-Ets-1 alone slightly increased the activity of the 7D176Prl-CAT construct. However, in the presence of GHF-1 at a concentration that by itself had little eect, c-Ets-1 produced a very strong . Control cells (C) and cells treated with 5 nM T3 or 10 mM forskolin (Fk) as in Figure 2 were incubated in the presence (black bars) or absence (light bars) of 13 nM IGF-1, and CAT activity was determined. The data are the mean+standard deviation of triplicate experiments Figure 6 Mitogen-activated protein kinase (MAPK) is required for the stimulation of the prolactin promoter by IGF-1 in GH4C1 cells. The 7D3000Prl-CAT plasmid was cotransfected with 40 mg of a vector expressing a dominant negative MAPK mutant (DN-MAPK). The cells were treated with 13 nM IGF-1, 5 nM T3, 10 mM forskolin (Fk) for 48 h and CAT activity determined stimulation of the proximal prolactin promoter, thus con®rming the important role of Ets on the activation of this promoter. In HeLa cells IGF-1 did not increase prolactin promoter activity. To analyse whether the levels of IGF-1 receptors in HeLa cells are too low to obtain this eect, the cells were transfected with the expression vector for the IGF-1 receptor. As shown in Figure 7b , in the absence of GHF-1, IGF-1 did not increase CAT activity in cells transfected with the IGF-1 receptor. In contrast, in the presence of GHF-1 there was a strong response to IGF-1 in cells expressing the IGF-1 receptor. This response was not found in cells transfected with c-Ets-1 alone, but in HeLa cells expressing both c-Ets-1 and GHF-1 a synergistic response which was further activated by IGF-1 was observed.
Since it has been reported that over-expression of cEts-1 appears to act cooperatively with GHF-1 to obtain a maximal Ras response in pituitary cells (Bradford et al., 1995) , we also examined the influence of transfection with the combination of c-Ets-1, Ras and GHF-1 on the response of the 7D3000Prl-CAT to IGF-1 in GH4C1 cells. Figure 8 shows the results obtained. Over-expression of GHF-1 alone did not further activate the prolactin promoter in GH4C1 cells that already contain high endogenous levels of this factor. The combination of c-Ets-1 and Ras produced a marked promoter activation, and GHF-1 further enhanced this response. GHF-2, a splice variant of the pituitary transcription factor, has been reported to inhibit the response to Ras (Bradford et al., 1995) . As shown in Figure 8 , GHF-2 had a strong negative eect on the prolactin promoter in GH4C1 cells and profoundly inhibited the response to c-Ets-1 and Ras. Of interest is the ®nding that IGF-1 signi®cantly increased CAT activity under the dierent conditions studied. A maximal activity was found when the growth factor was administered in cells overexpressing the combination of Ras, c-Ets-1 and GHF-1. In agreement with the results shown in Figure 4 , T3 showed an increase of basal CAT activity in the absence of Ras, but signi®cantly antagonized the stimulatory eect of the oncogene and c-Ets-1 both in the presence and absence of GHF-1. These results were similar to those found with forskolin, which also increased basal promoter activity but blocked the eect of these proteins. The stimulatory eect of IGF-1 was attenuated in the cells treated with T3 or forskolin and transfected Ras, c-Ets-1 and GHF-1. Similar experiments were repeated with the plasmid 7D176Prl-CAT. The results obtained were similar to those shown in Figure 8 with the longer construct. The combination of Ras, c-Ets-1 and GHF-1 produced a strong stimulation of the proximal promoter, and a further induction was found in the presence of IGF-1. Again, T3 and forskolin antagonized this stimulation as well as the stimulation by IGF-1 (data not shown).
To analyse the role of endogenous Ets transcription factors on IGF-1-induced prolactin gene expression, the in¯uence of dominant-negative Ets was also examined. GABP (Ouyang et al., 1996) and Ets-1 (Bradford et al., 1996) are Ets-related transcription factors which have been identi®ed in pituitary cells. However, the DNA-binding domain is highly conserved among the dierent members of Ets family of transcription factors which can recognize the same DNA sequences and, therefore, over-expression of the DNA binding domain of dierent Ets proteins should act as a dominant negative inhibitor. In this study we have used the DNA-binding domain of Ets-2. Figure 9 shows the eect of expression of dominant negative Ets on the response of the 7D176Prl-CAT construct to IGF-1 and activated Ras. The IGF-1 stimulation of the promoter is markedly reduced in the presence of dominant negative Ets, that also signi®cantly reduced Ras
Val12
-induced stimulation of the promoter.
An inhibitor of Pl3-kinase speci®cally blocks activation of the prolactin promoter by IGF-1
The autophosphorylation of the IGF-1 receptor results in the activation on other signaling pathways beside the Ras/MAPK pathway. One of these pathways involves the activation of the Pl-3 kinase (Myers et al., 1992) . To analyse whether this pathway could also contribute to the stimulatory eect of IGF-1 on the prolactin gene, the eect of IGF-1 was analysed in GH4C1 cells treated with wortmannin, a speci®c Pl3-kinase inhibitor. As shown in Figure 10 , basal promoter activity was not aected by this compound. However, treatment with wortmannin blocked the response of the 7D3000Prl-CAT construct to IGF-1, showing that the activation of the Pl3-kinase is required for the stimulatory eect of IGF-1 on the promoter. This inhibitory eect was speci®c since wortmannin did not modify the response to T3 or forskolin. Furthermore, the stimulation produced by EGF, other ligand of a tyrosine kinase receptor, was unaltered in GH4C1 cells treated with wortmannin.
Discussion
This paper presents evidence that IGF-1 stimulates prolactin gene transcription in rat pituitary GH4C1 cells. Prolactin mRNA levels are speci®cally increased by IGF-1, whereas expression of the other pituitary genes is not signi®cantly aected by the growth factor. This eect is mediated by sequences contained in the 5'-¯anking region of the prolactin gene. A partial stimulation is maintained in plasmids containing 101 base pairs of prolactin 5'-¯anking DNA. However, regulation by IGF-1 is lost in a plasmid extending to 776 base pairs. This suggests that the IGF-1 response element is located in the proximal promoter sequences in a region between 7101 and 776, although sequences between 7176 and 7101 are required to obtain a full induction. These results are parallel to those found with insulin, a hormone closely related to IGF-1, which has been also shown to stimulate prolactin gene transcription in these cells (Stanley, 1992) . However, whereas over-expression of the insulin receptor is required to observe activation of the prolactin promoter by insulin in transient transfection assays, the levels of endogenous IGF-1 receptors are sucient to mediate a signi®cant stimulation of this promoter by IGF-1. This suggests that IGF-1 may be a more relevant prolactin inducer than insulin, at least in cultured pituitary cells, since the response to IGF-1 Figure 9 Endogenous Ets proteins are required for stimulation of the prolactin promoter by IGF-1 in GH4C1 cells. The 7D176Prl-CAT plasmid (10 mg) was transfected alone or in combination with 50 mg of a dominant negative Ets vector (DNEts). CAT activity was determined in triplicate cultures of untreated cells and cells treated with 13 nM IGF-1 for 48 h. In other cultures the reporter plasmid was transfected with 6.7 mg of an expression vector for Ras Val12 in the presence and absence of the DN-Ets. The data are mean+standard deviation Figure 10 Inhibition of Pl-3 kinase activity blocks the stimulation of the prolactin promoter by IGF-1. GH4C1 cells were transfected with 10 mg of the 7D3000Prl-CAT plasmid and incubated for 48 h with 13 nM IGF-1, 5 nM triiodothyronine (T3), 10 mM forskolin (Fk) or 25 nM epidermal growth factor (EGF) in the absence (light bars) or presence (black bars) of 100 nM wortmannin. The data are mean+standard deviation of the CAT values obtained relies in endogenous rather than transfected receptors. EGF, another growth factor with a tyrosine kinase receptor also mediates prolactin gene transcription in pituitary cells (Day and Maurer, 1989) . However, as will be discussed below, the mechanisms by which IGF-1 and EGF regulate prolactin gene expression appear to be dierent.
Since the IGF-1 receptor is a tyrosine protein kinase, activation of prolactin gene expression by the growth factor in pituitary cells could involve the Ras/MAPK phosphorylation cascade. Our studies show that IGF-1 activation of prolactin gene expression is Rasdependent, since a dominant-negative Ras mutant blocks stimulation of the prolactin promoter by IGF-1. Activation of Ras in pituitary cells is followed by the downstream stimulation of the serine/threonine kinases Raf kinase, MAPKK and MAPK (Conrad et al., 1994) . We have reported that MAPK is transiently activated after incubation with IGF-1 in pituitary cells (Castillo and Aranda, 1997) , and our data show that MAPK activation is required for the regulation of prolactin gene expression by IGF-1 in GH4C1 cells, since expression of dominant-negative MAPK inhibits the eect of IGF-1.
Ets, which appears to mediate transcriptional responses to the MAPK pathway, is an important component of prolactin promoter activation by Ras (Bradford et al., 1995; Howard and Maurer, 1995) . This suggests that activation of the MAPK pathway leading to phosphorylation of an Ets factor could be involved in the response of the prolactin promoter to IGF-1. The involvement of Ets-proteins in IGF-1-induced prolactin gene transcription is suggested by the experiment with the dominant-negative Ets plasmid. Expression of high levels of an Ets binding domain, that acts as dominant-negative Ets factor, strongly reduces the IGF-1 response. The regulation of prolactin gene transcription by IGF-1 and insulin is similar. Both responses are mediated by sequences located in the proximal promoter and require Ets (Stanley, 1992; Jacob and Stanley, 1994; Jacob et al., 1995) . The insulin responsive site in the prolactin promoter is composed of a dyad of an Ets-binding site separated by 10-bp, and this element is also involved in the response to IGF-1 since mutation of the Ets motifs abolishes induction by IGF-1. Although our work did not address the question of which members of the Etsfamily are involved in the regulation of prolactin gene expression by IGF-1 in GH4C1 cells, the identity of at least one endogenous Ets factor in pituitary cells has been very recently reported. The Ets protein GABP binds the prolactin promoter and is phosphorylated by MAPK in insulin-treated pituitary cells (Ouyang et al., 1996) .
Although EGF also produces activation of the rat prolactin promoter in pituitary cells, it does so by a mechanism dierent from that used by IGF-1 Gutierrez-Hartmann, 1994, 1995; Howard and Maurer, 1995) . First, whereas activation of the prolactin promoter by IGF-1 requires the sequential activation of Ras and MAPK, activation by EGF is Ras-and MAPK-independent. Second, Ets is necessary for the action of IGF-1, but a dominant-negative Ets does not aect EGF stimulation. Third, EGF treatment inhibits activation of the prolactin promoter by oncogenic Ras, whereas IGF-1 cooperates with Ras to activate this promoter. These results show that prolactin gene regulation by IGF-1 is mediated by a signal transduction pathway that is separate to that used by EGF, and most likely similar to that used by insulin.
Expression of the prolactin gene is under transcriptional control of the pituitary-speci®c factor GHF-1 which binds to several sites in the proximal promoter and in the upstream enhancer (Bodner and Karin, 1987) . Furthermore, a number of studies have shown that GHF-1 is important for mediating hormonal regulation of the prolactin promoter. However, the in¯uence of IGF-1 on the prolactin gene is not secondary to changes in GHF-1 gene expression, since IGF-1 alters neither GHF-1 mRNA levels nor GHF-1 promoter activity in GH4C1 cells (Castillo and Aranda, 1997) . These results do not exclude the participation of the pituitary-speci®c factor in the regulation of prolactin gene expression by IGF-1. Ets factors frequently cooperate with other transcription factors to mediate transcriptional responses, and cooperation between GHF-1 and Ets most likely provides a mechanism permitting the prolactin transcriptional response to activation of the Ras/MAPK pathway (Bradford et al., 1995; Howard and Maurer, 1995) . Our results show that promoter sequences (from 7176 to 7101), which contain a GHF-1 binding site overlapping an Ets binding site, signi®cantly contribute to the induction of promoter activity by IGF-1. Furthermore, we have been able to reconstitute the IGF-1 response in non-pituitary HeLa cells transfected with IGF-1 receptors, and in these cells induction of the prolactin promoter by IGF-1 requires the presence of GHF-1. In addition, con®rming a very recent report (Bradford et al., 1997) , we ®nd a synergistic interaction between c-Ets-1 and GHF-1 in HeLa cells. Under these conditions the eect of IGF-1 on the promoter was maximal, thus con®rming the implication of these transcription factors in basal and IGF-1 regulated prolactin promoter activity. The ability of the splice variant GHF-2 to inhibit this response, supports the interpretation that GHF-1 is involved in the eect of IGF-1 (Bradford et al., 1995) .
In some aspects our ®ndings con®rm recent reports which examined the ability of Ras to activate the prolactin promoter. Bradford et al. (1995) have shown that over-expression of GHF-1 and c-Ets-1 enhanced responsiveness of the prolactin promoter to Ras. However, there are discrepancies between our results and those obtained by these authors. The studies by Bradford et al. (1996 Bradford et al. ( , 1997 describe the sequences mediating the Ras and Ets response as located between 7217 and 7209. In contrast, our results show that a promoter fragment extending only to 7176 bp, which does not contain these sequences, is also strongly responsive to Ras in pituitary cells. Furthermore, our data also demonstrate that a strong Ets-responsive element exists in this region. Our results are, however, in agreement with others showing that the proximal prolactin promoter contains other Ets-binding sites which can mediate transcriptional responses to Ras. Howard and Maurer (1995) have shown that the composite Ets/GHF-1 binding site located between 7150 and 7165 is signi®cantly activated by Ras and can mediate transcriptional responses to multiple second messengers and hormones, including EGF.
Taken together, these ®ndings suggest that several Etsbinding sites contribute to regulation of prolactin gene expression by dierent signaling pathways. The most proximal Ets sites located between 758 and 7101 appear to mediate responses to both insulin and IGF-1 (Jacob et al., 1995 and this study) , the Ets site between 7150 and 7165 is involved in regulation by EGF and phorbol esters (Howard and Maurer, 1995) and most likely contributes to the IGF-1 response, and these elements as well as the more distal Ets-binding site confer Ras-responsiveness to this promoter.
Although Ras, MAPK and Ets are required for the IGF-1 eect, activation of additional pathways could also contribute to a full IGF-1 response. This is suggested by the ®nding that IGF-1 is able to increase prolactin promoter activity even after expression of activated Ras, or over-expression of cEts-1. If IGF-1 was solely stimulating the promoter via activation of Ras, it was expected that when this pathway was already activated in the presence of oncogenic Ras, the eect of IGF-1 should no longer be present. This prompted us to investigate the possibility that the Pl-3 kinase signaling pathway could be also required for the stimulatory eect of IGF-1. Our results show that activation of the prolactin promoter by IGF-1 is prevented if the cells are incubated with wortmannin, an speci®c inhibitor of Pl-3 kinase. Therefore, at least two dierent pathways are required for the induction of prolactin gene expression by IGF-1. The requirement of Ras activation is clear, since no eect of IGF-1 was observed when the endogenous pathway was blocked with the dominant-negative mutant, and the requirement of Pl-3 kinase activation is shown by the inhibitory eect of wortmannin. It is interesting that this inhibitor did not aect the stimulation of the prolactin promoter by EGF, again showing the divergent pathways used by IGF-1 and EGF on the stimulation of the prolactin gene.
We have observed that the thyroid hormone T3 is a potent stimulator of the expression of the endogenous prolactin gene in GH4C1 cells, as demonstrated by the increases of prolactin mRNA levels observed in T3-treated cells. Furthermore, in agreement with previous results (Day and Maurer, 1989) , T3 signi®cantly stimulated the activity of prolactin promoter constructs containing the upstream regulatory elements. T3 exerts this stimulatory eect despite the fact that it decreases GHF-1 gene expression in GH4C1 cells (Sanchez-Pacheco et al., 1995) . However, T3 has a dual eect on the prolactin promoter. We found that this hormone is a potent antagonist of the induction of the prolactin promoter by Ras and IGF-1. T3 was able to strongly decrease the response to Ras even in the presence of excess amounts of c-Ets-1 and GHF-1, when the stimulation of the prolactin promoter was maximal. The antagonistic eect of T3 was even more marked on the proximal promoter, where T3 is not stimulatory under basal conditions. This suggests that the mechanism by which T3 antagonizes the eect of Ras is dierent from that responsible for stimulation of the prolactin promoter, since the sequences mediating both eects were dierent. To our knowledge this is the ®rst observation of a cross talk between the T3 receptor and the Ras pathway in pituitary cells. If the antagonism between T3 and Ras were extensive to transcriptional regulation of other genes, this could represent a major mechanism of regulation of gene expression, and cell growth and dierentiation.
Since Ras activation is one of the pathways by which IGF-1 elicits the induction of the prolactin promoter, the antagonism of Ras induction by T3 is apparently inconsistent with the ®nding that T3 and IGF-1 have an additive eect. Although we do not know the reason for this discrepancy, it is possible that the transient activation of Ras by IGF-1, versus the sustained expression of the activated oncoprotein in cells transfected with oncogenic ras may play a role in this dierent behaviour. Similar results were found with cAMP, another well known stimulator of prolactin promoter activity. Incubation with forskolin, that activates PKA, increases prolactin promoter activity in GH4C1 cells, and the eects of IGF-1 and forskolin were additive. However, cAMP also reduced the promoter response to Ras, con®rming previous observations that the Ras and PKA pathways are mutually antagonistic (Conrad and Gutierrez-Hartmann, 1992) . Although the mechanism of this antagonism has not yet been clari®ed, it is known that cAMP can decrease MAPK activity in dierent systems, and recent studies have shown that IGF-1 treatment activates MAPK in pituitary GC cells overexpressing the IGF-1 receptor, and that forskolin attenuates IGF-1 induced MAPK activity in these cells (Webster et al., 1994) .
In summary, our results show that the prolactin gene provides an excellent model for the study of the mechanisms of interaction among dierent signaling pathways in transcriptional regulation. The nuclear thyroid hormone receptor, the IGF-1 membrane receptor, the ras oncogene, the Pl-3 kinase pathway and the cAMP pathway are interconnected with one another in a complex manner that provides an integrated response of the prolactin gene in the pituitary cell.
Materials and methods
RNA extraction and hybridization
GH4C1 cells, derived from a rat pituitary tumor, were cultured in DMEM medium containing 10% fetal calf serum. The cells were transferred to a medium containing a hormone-stripped serum by treatment with resin AG-1-x100 and activated charcoal, and the experiments were started 1 day later in serum-free medium. The cells were treated for 48 h with 13 nM IGF-1, 5 nM T3 or 10 mM forskolin. Total RNA was extracted from the cell cultures with guanidine thiocyanate as described (Garcia-Villalba et al., 1996; Sanchez-Pacheco et al., 1995) . The RNA was run in 1% formaldehyde-agarose gels and transferred to nylonnitrocellulose membranes (Nytran) for Northern blot analysis. The RNA was stained with 0.02% methylene blue. The blots were hybridized with cDNA probes for rat prolactin (Gubbins et al., 1980) , GH (Seeburg et al., 1977) or GHF-1/Pit-1 (Bodner and Karin, 1987) labeled by nick translation. Hybridizations were at 428C with 50% formamide and the more stringent wash was at 428C with 16SSC-0.1% SDS. Quanti®cation of mRNA levels was carried out by densitometric scan of the autoradiograms. The values obtained from exposures in the linear range were always corrected by the amount of RNA applied in each lane which was determined by densitometry of the stained membranes.
Plasmids
The plasmids 73000Prl-CAT and 7176Prl-CAT contain 5'-¯anking sequences of the rat prolactin promoter in the pBL-CAT2 vector with the thymidine kinase promoter deleted (Stanley, 1989) . Since this vector contains an AP-1-like sequence at +34/+39 which could mask some promoter responses (Kushner et al., 1994) , a 301 base pairs fragment containing these sequences was deleted by digestion with AatII and NarI. The constructs were then blunt-ended and religated to give the 73000DPrl-CAT and 7176DPrl-CAT plasmids. A deletion to 7423 was obtained by digestion of 73000Prl-CAT and 73000DPrl-CAT with HindIII. Other 5' deletion Prl-CAT plasmids (7D101Prl-CAT, 7101Prl-CAT, 7D76Prl-CAT and 776Prl-CAT) were produced by polymerase chain reaction (PCR) ampli®cation using 5' oligonucleotides corresponding to sequences 7101 to 781 and 776 to 758, respectively. The 3' oligonucleotide corresponded to sequences +57 to +74. The plasmids 7101mutPrl-CAT and 7D101mutPrl-CAT were produced by PCR using the 5' oligonucleotide primer ATGACTTGGATATTC-GATTGGGAGGTTGGGAGTTCGCCTG in which the two Ets binding sites reported to be required for insulin regulation of the prolactin promoter have been mutated. The insulin response element is composed of a dyad of the sequence GGAA(A/G)(T/A)(A/G) separated by 10-bp (Jacob and Stanley, 1994; Jacob et al., 1995) . The vectors for GHF-1 and GHF-2 contain the cDNA sequences of both isoforms under control of the constitutively active Rous sarcoma virus promoter (Theill et al., 1992) . Constitutive expression vectors for oncogenic Ha-ras Val12 (CaleÂ s et al., 1988) and v-raf (Kolch et al., 1991) were also used in transient transfection assays. In these assays the cells were co-transfected with the prolactin reporter construct and the corresponding expression vector. Similar experiments were carried out in cells transfected with a vector for dominant negative forms of the ras oncogene. This vector contains the dominant inhibitory Ha-ras Asn17 mutant (Feig and Cooper, 1988) . A dominant negative MAPK vector (encoding the Chinese hamster p44 MAPK mutated in the kinase domain) has been previously described (Meloche et al., 1992) . Expression vectors for c-Ets-1 and ERM have also been previously described (Monte et al., 1995) . The dominant negative Ets vector, encodes the DNA binding domain of Ets-2 (Schneikert et al., 1992 ). An expression vector for the human IGF-1 receptor (pBPV-IGF1-R) described by Kato et al. (1993) was used to express this receptor in GH4C1 and HeLa cells.
Cell culture and transfections GH4C1 cells were transfected by electroporation as previously described (Garcia-Villalba et al., 1996; Sanchez-Pacheco et al., 1995) . Ten micrograms of the reporter plasmids were mixed with 30 ± 40 million cells and exposed to a high-voltage pulse (200 ± 250 V, 960 mF) by using a Bio-Rad electroporator with a capacitor extender. The cells from each electroporation were split into dierent culture plates in DMEM containing 10% AG1x8 resin-charcoal stripped newborn calf serum. Treatments were administered 14 h later in serum-free medium. HeLa cells were grown in DMEM containing 10% fetal calf serum. HeLa cells were plated 24 h prior to transfection by calcium phosphate with reporter constructs. In co-transfection experiments the reporter plasmids were transfected with the amounts of expression vectors indicated in the ®gures. In all cases the total amount of DNA among dierent transfections was kept constant by the addition of empty noncoding expression vectors (RSV-0 and pSG5-0). Each transfection also received 1 mg of a luciferase vector as a control of transfection eciency. Each treatment with the ligands was performed at least in duplicate cultures that normally exhibited less than 10% variation in CAT or luciferase activity. CAT activity was determined by incubation of the cell extracts with [
14 C]chloramphenicol. The unreacted and acetylated [
14 C]chloramphenicol were separated by thin layer chromatography, identi®ed by autoradiography, and quanti®ed. The data are expressed as the percentage of acetylated forms after each treatment. Luciferase activity was determined with a Berthold luminometer. Each experiment was repeated at least two or three times with similar relative dierences in regulated expression.
